EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C29H44N8O3 |
| Net Charge | 0 |
| Average Mass | 552.724 |
| Monoisotopic Mass | 552.35364 |
| SMILES | CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1 |
| InChI | InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34) |
| InChIKey | GYQYAJJFPNQOOW-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Roles: | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1). apoptosis inducer Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| Application: | antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| gilteritinib (CHEBI:145372) has role antineoplastic agent (CHEBI:35610) |
| gilteritinib (CHEBI:145372) has role apoptosis inducer (CHEBI:68495) |
| gilteritinib (CHEBI:145372) has role EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor (CHEBI:62434) |
| gilteritinib (CHEBI:145372) is a N-methylpiperazine (CHEBI:46920) |
| gilteritinib (CHEBI:145372) is a aromatic amine (CHEBI:33860) |
| gilteritinib (CHEBI:145372) is a monomethoxybenzene (CHEBI:25235) |
| gilteritinib (CHEBI:145372) is a oxanes (CHEBI:46942) |
| gilteritinib (CHEBI:145372) is a piperidines (CHEBI:26151) |
| gilteritinib (CHEBI:145372) is a primary carboxamide (CHEBI:140324) |
| gilteritinib (CHEBI:145372) is a pyrazines (CHEBI:38314) |
| gilteritinib (CHEBI:145372) is a secondary amino compound (CHEBI:50995) |
| IUPAC Name |
|---|
| 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide |
| INNs | Source |
|---|---|
| gilteritinibum | WHO MedNet |
| gilteritinib | WHO MedNet |
| gilteritinib | WHO MedNet |
| giltéritinib | WHO MedNet |
| Synonyms | Source |
|---|---|
| ASP-2215 | DrugBank |
| ASP2215 | DrugBank |
| ASP 2215 | ChemIDplus |
| 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide | IUPAC |
| 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide | ChemIDplus |
| Brand Name | Source |
|---|---|
| Xospata | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| DB12141 | DrugBank |
| D10709 | KEGG DRUG |
| Gilteritinib | Wikipedia |
| Registry Numbers | Sources |
|---|---|
| CAS:1254053-43-4 | ChemIDplus |
| Citations |
|---|